LIVZON PHARMA's first-quarter net profit attributable to its parent company was RMB 577 million, a year-on-year decrease of 9.39%.

LIVZON PHARMA (01513) announced that in the first quarter of 2026, the company achieved operating income of RMB 2.871 billion, a year-on-year decrease of 9.73%; net profit attributable to shareholders of the listed company was RMB 577 million, a year-on-year decrease of 9.39%. Due to the impact of the transitional period of industry policy adjustments and seasonal fluctuations such as influenza and respiratory infections in the first quarter, the company's operating income fluctuated compared to the same period last year, but the overall business performance of the company remained stable, and the operating quality of core business remained strong. Specific reasons for the fluctuation in operating income include: in the first quarter of 2026, the domestic influenza and respiratory disease incidence rate decreased compared to the same period in 2025, leading to corresponding adjustments in the income of respiratory-related products in the antiviral granule and diagnostic plate divisions; the 11th batch of centralized drug procurement policy entered the implementation stage, and some products included in the procurement variety are in a transitional period of price system adjustment, which has a certain impact on income in the short term; the raw material division was affected by seasonal fluctuations in customer orders, leading to adjustments in income compared to the same period last year. At the same time, the company actively implemented response measures to continuously improve resilience and risk resistance through cost optimization, operational efficiency enhancement, customer structure optimization, and accelerated commercialization of innovative products. The company is focusing on three key areas: first, accelerating the commercialization of innovative products, the company's core innovative products such as injectable aliprazole microspheres and injectable leuprolide acetate microspheres (for endometriosis) have been successfully included in the national medical insurance catalogue and are in the rapid market expansion phase, with the release of medical insurance access dividends and deepening clinical promotion, the innovative drug segment is expected to become a new engine of company performance growth; secondly, continuous realization of R&D pipeline, key products in the late stage of research and development or applying for listing, such as Lekoncita monoclonal antibody, JP-1366 tablets, recombinant human follicle-stimulating hormone, will continue to enter the commercialization stage, providing solid support for the company's medium to long-term development; thirdly, deepening international layout, the acquisition project of IMP in Vietnam is progressing as scheduled, the international registration process is accelerating, and it is expected to open up new growth space.